

Product Name: Tankyrase Inhibitors (TNKS) 49 Revision Date: 01/10/2021

Product Data Sheet

Tankyrase Inhibitors (TNKS) 49

A8601 Cat. No.:

CAS No.:

Formula: C24H24N4O3S


M.Wt: 448.54

TNKS 49;TNKS49;TNKS-49 Synonyms:

Target: Chromatin/Epigenetics

PARP Pathway:

Storage: Store at -20°C



Solvent & Solubility

≥22.45 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	2.2295 mL	11.1473 mL	22.2946 mL
	5 mM	0.4459 mL	2.2295 mL	4.4589 mL
	10 mM	0.2229 mL	1.1147 mL	2.2295 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Tankyrase inhibitor	
IC ₅₀ & Target		
	Cell Viability Assay	
In Vitro	Cell Line:	SW480-TBC cell lines
	Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining
		a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or
		shake it in the ultrasonic bath for a while. Stock solution can be stored below
		-20°C for several months.
	Reacting conditions:	24 h; IC50=1.9 nM

	Applications:	Tankyrase Inhibitors (TNKS) 49, phenoxy compounds, has a good enzymatic			
	T THE TANK THE THE TANK THE THE THE TANK THE TANK THE TANK THE THE TANK THE THE THE THE THE T	potency and cellular potency with IC50 value of 1.9 nM in the SW480-TBC			
		cellular assay. The compound demonstrated excellent potencies in TNKS2			
		autoparsylation assay and the two additional functional cellular assays.			
	Animal experiment	Animal experiment			
In Vivo	Animal models:	Athymic nude mice.			
	Dosage form:	10 and 50 mg/kg; q.d.; oral taken			
	Applications:	Tankyrase Inhibitors (TNKS) 49 was evaluated for Wnt-pathway specific pharmacological activity in mouse tumor pharmacodynamic (PD) models. Upon once daily oral administration (at 10 and 50 mg/kg) to mice (n=4) bearing human DLD-1 tumors for 3 days, both compounds exhibited statistically significant, dose-dependent axin2 accumulation (2.1- to 3-fold) and inhibition of STF (70-79%) at day 3 (24 h after the last dose).			
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.			

Product Citations

See more customer validations on www.apexbt.com.

References

[1] Hua Z, Bregman H, Buchanan J L, et al. Development of Novel Dual Binders as Potent, Selective, and Orally Bioavailable Tankyrase Inhibitors[J]. Journal of medicinal chemistry, 2013, 56(24): 10003-10015.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APE, BIO

APE, BIO

APE BIO

APE BIO

APE, BIO

APE BIO